Repligen Corp (RGEN) shareholders
Close on Nov 17, 2026Market cap $10.37BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC Joint filing with Abigail P. Johnson (13.00%) | 7,361,318 | 13.00% | 13G (passive) amendment | Sep 30, 2026 |
| BlackRock, Inc. | 5,198,107 | 9.30% | 13G (passive) amendment | Mar 31, 2025 |
| Vanguard Capital Management | 2,825,579 | 5.00% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RGEN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5,384,938 | 8.42% | $734.72M | −608,116 | 0.01% |
| FMR LLC | 3,326,690 | 5.20% | $453.89M | +439,904 | 0.02% |
| United Capital Financial Advisers, LLC | 2,790,650 | 4.37% | $380.76M | +16,670 | 2.10% |
| Vanguard Capital Management LLC | 2,411,171 | 3.77% | $328.98M | +14,660 | 0.01% |
| Vanguard Portfolio Management LLC | 2,312,825 | 3.62% | $315.56M | +7,731 | 0.01% |
| Maverick Capital Ltd | 1,984,554 | 3.10% | $270.77M | +465,749 | 2.39% |
| State Street Corp | 1,800,530 | 2.82% | $245.68M | +23,245 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 1,752,274 | 2.74% | $239.08M | −3,125,867 | 0.02% |
| Massachusetts Financial Services Co /Ma/ | 1,617,021 | 2.53% | $220.61M | +219,506 | 0.07% |
| Wasatch Advisors LP | 1,590,251 | 2.49% | $216.97M | +346,720 | 1.42% |
| Ameriprise Financial Inc | 1,576,132 | 2.47% | $215.05M | +650,918 | 0.04% |
| Bank of New York Mellon Corp | 1,522,859 | 2.38% | $207.78M | −8,543 | 0.03% |
| T. Rowe Price Investment Management, Inc. | 1,411,619 | 2.21% | $192.60M | +44,939 | 0.13% |
| Invesco Ltd. | 1,387,242 | 2.17% | $189.28M | +108,987 | 0.01% |
| Holocene Advisors, LP | 1,292,191 | 2.02% | $176.31M | +583,302 | 0.40% |
| Rtw Investments, LP | 1,240,637 | 1.94% | $169.27M | +34,637 | 1.45% |
| Geode Capital Management, LLC | 1,062,476 | 1.66% | $145.00M | −1,981 | 0.01% |
| Congress Asset Management Co /Ma | 1,012,226 | 1.58% | $138.11M | +214,359 | 0.85% |
| Conestoga Capital Advisors, LLC | 980,983 | 1.53% | $133.85M | −116,800 | 2.91% |
| Goldman Sachs Group Inc | 965,411 | 1.51% | $131.72M | +314,064 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 480 | 66M | 100.0% | 98 / 174 | 143 / 56 | 10M | 9M |
| Q1 2026 | 445 | 66M | 100.0% | 69 / 166 | 131 / 92 | 15M | 6M |
| Q4 2025 | 475 | 62M | 97.8% | 96 / 152 | 143 / 62 | 10M | 8M |
| Q3 2025 | 453 | 60M | 94.0% | 80 / 159 | 151 / 65 | 12M | 10M |
| Q2 2025 | 444 | 59M | 91.7% | 74 / 129 | 174 / 69 | 7M | 6M |
| Q1 2025 | 441 | 58M | 90.2% | 61 / 172 | 129 / 45 | 5M | 3M |
| Q4 2024 | 431 | 56M | 88.0% | 60 / 136 | 159 / 67 | 5M | 5M |
| Q3 2024 | 445 | 56M | 87.4% | 74 / 157 | 157 / 81 | 14M | 6M |
| Q2 2024 | 455 | 56M | 88.1% | 66 / 160 | 165 / 92 | 6M | 8M |
| Q1 2024 | 486 | 58M | 90.3% | 61 / 173 | 168 / 36 | 3M | 5M |
| Q4 2023 | 467 | 59M | 92.2% | 77 / 154 | 160 / 44 | 5M | 3M |
| Q3 2023 | 440 | 57M | 89.6% | 56 / 164 | 156 / 61 | 5M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
538 funds held RGEN in Q2 2026, 34% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of RGEN | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF | 1,814,742 | 2.84% | $247.60M | 0.20% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,702,844 | 2.66% | $232.34M | 0.01% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,229,445 | 1.92% | $167.75M | 0.09% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 963,028 | 1.51% | $131.40M | 0.89% | Jun 30, 2026 |
| MFS Mid Cap Growth Fund | 862,365 | 1.35% | $106.89M | 0.78% | May 31, 2026 |
| Vanguard Small-Cap Growth Index Fund | 709,041 | 1.11% | $96.74M | 0.21% | Jun 30, 2026 |
| Wasatch Core Growth Fund | 673,975 | 1.05% | $91.96M | 3.08% | Jun 30, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 631,943 | 0.99% | $86.22M | 3.07% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 619,174 | 0.97% | $84.48M | 0.91% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 608,541 | 0.95% | $83.03M | 0.08% | Jun 30, 2026 |
| Select Medical Technology and Devices Portfolio | 520,000 | 0.81% | $64.45M | 2.17% | May 31, 2026 |
| Columbia Small Cap Growth Fund | 508,986 | 0.80% | $63.09M | 1.72% | May 31, 2026 |
| Select Health Care Portfolio | 460,000 | 0.72% | $57.02M | 0.99% | May 31, 2026 |
| Conestoga Small Cap Fund | 431,645 | 0.68% | $58.89M | 2.88% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 428,500 | 0.67% | $53.11M | 0.02% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Olivier Loeillot | Chief Executive Officer, Director | 45,788 | 0.07% | Oct 6, 2026 |
| Brian Robb Douglass | CHIEF PRODUCT OFFICER | 8,685 | 0.01% | Oct 8, 2026 |
| Jason K. Garland | CFO | 18,408 | 0.03% | Sep 28, 2026 |
| Violetta Hughes | CHIEF ACCOUNTING OFFICER | 6,331 | 0.01% | Sep 2, 2026 |
| Ralf Kuriyel | Senior VP, R&D | 20,062 | 0.03% | Mar 23, 2026 |
| James Bylund | Chief Operating Officer | 25,423 | 0.04% | Mar 23, 2026 |
| Manner Carrie Eglinton | Director | 5,461 | 0.01% | May 18, 2026 |
| Rohin Mhatre | Director | 5,014 | 0.01% | May 18, 2026 |
| Martin D. Madaus | Director | 8,392 | 0.01% | May 18, 2026 |
| Karen A. Dawes | Director | 92,816 | 0.15% | May 18, 2026 |
| Nicolas Barthelemy | Director | 5,436 | 0.01% | May 18, 2026 |
| Glenn P. Muir | Director | 40,051 | 0.06% | May 18, 2026 |
| Konstantin Konstantinov | Director | 3,889 | 0.01% | May 18, 2026 |
| Margaret Pax | Director | 3,011 | 0.00% | May 18, 2026 |
| Anthony Hunt | Director | 89,062 | 0.14% | Mar 3, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Brian Robb Douglass CHIEF PRODUCT OFFICER | Oct 6, 2026 | Award | +700 | – | – | 8,685 |
| Olivier Loeillot Chief Executive Officer, Director | Oct 5, 2026 | Sale(10b5-1 plan) | −4,202 | $190.00 | $798.38K | 45,788 |
| Olivier Loeillot Chief Executive Officer, Director | Oct 5, 2026 | Option exercise | +4,202 | $154.96 | $651.14K | 49,990 |
| Olivier Loeillot Chief Executive Officer, Director | Oct 5, 2026 | Sale(10b5-1 plan) | −1,333 | $178.75 | $238.27K | 45,788 |
| Olivier Loeillot Chief Executive Officer, Director | Oct 2, 2026 | Tax withholding | −1,248 | $181.70 | $226.76K | 47,121 |
| Jason K. Garland CFO | Sep 25, 2026 | Tax withholding | −421 | $189.68 | $79.86K | 18,408 |
| Olivier Loeillot Chief Executive Officer, Director | Sep 24, 2026 | Sale(10b5-1 plan) | −4,542 | $190.00 | $862.98K | 48,369 |
| Olivier Loeillot Chief Executive Officer, Director | Sep 24, 2026 | Option exercise | +4,542 | $155.38 | $705.74K | 52,911 |
| Olivier Loeillot Chief Executive Officer, Director | Sep 24, 2026 | Option exercise | +8,404 | $154.96 | $1.30M | 56,773 |
| Olivier Loeillot Chief Executive Officer, Director | Sep 24, 2026 | Sale(10b5-1 plan) | −8,404 | $190.00 | $1.60M | 48,369 |
| Olivier Loeillot Chief Executive Officer, Director | Sep 21, 2026 | Sale(10b5-1 plan) | −5,426 | $180.00 | $976.68K | 48,369 |
| Olivier Loeillot Chief Executive Officer, Director | Sep 21, 2026 | Option exercise | +5,426 | $141.79 | $769.35K | 53,795 |
| Olivier Loeillot Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −3,035 | $165.90 | $503.51K | 48,369 |
| Olivier Loeillot Chief Executive Officer, Director | Sep 3, 2026 | Tax withholding | −2,842 | $169.61 | $482.03K | 51,404 |
| Violetta Hughes CHIEF ACCOUNTING OFFICER | Sep 1, 2026 | Tax withholding | −277 | $170.02 | $47.10K | 6,331 |
| Olivier Loeillot Chief Executive Officer, Director | Aug 20, 2026 | Option exercise | +5,426 | $141.79 | $769.35K | 59,672 |
| Olivier Loeillot Chief Executive Officer, Director | Aug 20, 2026 | Sale(10b5-1 plan) | −5,426 | $180.00 | $976.68K | 54,246 |
| Jason K. Garland CFO | Jul 16, 2026 | Sale(10b5-1 plan) | −530 | $150.00 | $79.50K | 18,829 |
| Jason K. Garland CFO | Jun 25, 2026 | Sale(10b5-1 plan) | −733 | $145.00 | $106.29K | 19,359 |
| Karen A. Dawes Director | May 14, 2026 | Award | +995 | – | – | 92,816 |
| Rohin Mhatre Director | May 14, 2026 | Award | +995 | – | – | 5,014 |
| Konstantin Konstantinov Director | May 14, 2026 | Award | +995 | – | – | 3,889 |
| Manner Carrie Eglinton Director | May 14, 2026 | Award | +995 | – | – | 5,461 |
| Margaret Pax Director | May 14, 2026 | Award | +995 | – | – | 3,011 |
| Martin D. Madaus Director | May 14, 2026 | Award | +995 | – | – | 6,581 |
| Nicolas Barthelemy Director | May 14, 2026 | Award | +995 | – | – | 5,436 |
| Glenn P. Muir Director | May 14, 2026 | Award | +995 | – | – | 40,051 |
| Glenn P. Muir Director | May 7, 2026 | Option exercise | +2,434 | $38.76 | $94.34K | 39,056 |
| Brian Robb Douglass CHIEF PRODUCT OFFICER | May 7, 2026 | Tax withholding | −334 | $126.43 | $42.23K | 7,985 |
| Olivier Loeillot Chief Executive Officer, Director | Apr 21, 2026 | Sale(10b5-1 plan) | −3,832 | $140.00 | $536.48K | 54,246 |
| Violetta Hughes CHIEF ACCOUNTING OFFICER | Mar 5, 2026 | Award | +2,466 | – | – | 6,608 |
| Jason K. Garland CFO | Mar 5, 2026 | Award | +7,751 | – | – | 20,092 |
| Olivier Loeillot Chief Executive Officer | Mar 5, 2026 | Award | +24,134 | – | – | 58,078 |
| James Bylund Chief Operating Officer | Mar 5, 2026 | Award | +7,751 | – | – | 25,423 |
| Ralf Kuriyel Senior VP, R&D | Mar 5, 2026 | Award | +5,284 | – | – | 20,062 |
| James Bylund Chief Operating Officer | Mar 4, 2026 | Tax withholding | −62 | $125.84 | $7.80K | 17,672 |
| James Bylund Chief Operating Officer | Mar 4, 2026 | Award | +125 | – | – | 17,734 |
| Ralf Kuriyel Senior VP, R&D | Mar 4, 2026 | Tax withholding | −42 | $125.84 | $5.29K | 14,778 |
| Ralf Kuriyel Senior VP, R&D | Mar 4, 2026 | Award | +125 | – | – | 14,820 |
| Jason K. Garland CFO | Mar 2, 2026 | Tax withholding | −715 | $124.97 | $89.35K | 12,341 |
| Anthony Hunt Director | Mar 2, 2026 | Tax withholding | −9,897 | $124.97 | $1.24M | 89,062 |
| Brian Robb Douglass CHIEF PRODUCT OFFICER | Mar 2, 2026 | Tax withholding | −221 | $124.97 | $27.62K | 8,319 |
| Olivier Loeillot Chief Executive Officer, Director | Mar 2, 2026 | Tax withholding | −1,610 | $124.97 | $201.20K | 33,944 |
| Ralf Kuriyel Senior VP, R&D | Mar 2, 2026 | Tax withholding | −923 | $124.97 | $115.35K | 14,695 |
| James Bylund Chief Operating Officer | Mar 2, 2026 | Tax withholding | −2,433 | $124.97 | $304.05K | 17,609 |
| Jason K. Garland CFO | Feb 27, 2026 | Tax withholding | −327 | $128.73 | $42.09K | 13,056 |
| Olivier Loeillot Chief Executive Officer, Director | Feb 27, 2026 | Tax withholding | −344 | $128.73 | $44.28K | 35,554 |
| Ralf Kuriyel Senior VP, R&D | Feb 27, 2026 | Tax withholding | −444 | $128.73 | $57.16K | 15,618 |
| James Bylund Chief Operating Officer | Feb 27, 2026 | Tax withholding | −1,478 | $128.73 | $190.26K | 20,042 |
| Brian Robb Douglass CHIEF PRODUCT OFFICER | Dec 31, 2025 | Award | +2,288 | – | – | 8,540 |
| Karen A. Dawes Director | Dec 17, 2025 | Sale | −275 | $161.00 | $44.28K | 91,821 |
| Glenn P. Muir Director | Dec 16, 2025 | Option exercise | +3,366 | $26.12 | $87.92K | 36,622 |
| Anthony Hunt Director | Dec 4, 2025 | Other | −2,000 | – | – | 98,959 |
| Olivier Loeillot Chief Executive Officer, Director | Nov 25, 2025 | Sale(10b5-1 plan) | −7,041 | $170.00 | $1.20M | 35,898 |
| James Bylund Chief Operating Officer | Nov 18, 2025 | Sale | −2,191 | $151.21 | $331.30K | 21,520 |
| Anthony Hunt Director | Nov 13, 2025 | Option exercise | +2,952 | $33.87 | $99.98K | 83,695 |
| Anthony Hunt Director | Nov 13, 2025 | Sale | −1,956 | $157.11 | $307.31K | 80,743 |
| Anthony Hunt Director | Nov 13, 2025 | Sale | −5,737 | $156.22 | $896.23K | 82,699 |
| Anthony Hunt Director | Nov 13, 2025 | Sale | −3,000 | $155.45 | $466.35K | 88,436 |
| Anthony Hunt Director | Nov 13, 2025 | Sale | −2,500 | $154.32 | $385.80K | 91,436 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Repligen's stock actually held short. Settlement fails (shares not delivered on time) peaked at 17,437 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Olivier Loeillot Officer, Director | Oct 5, 2026 | 4,202 | $798.38K | Oct 5, 2026 | Stock Option Exercise |
| Olivier Loeillot Officer, Director | Oct 5, 2026 | 1,333 | $238.27K | Oct 5, 2026 | Restricted Stock Vesting |
| Olivier Loeillot Officer, Director | Sep 24, 2026 | 12,946 | $2.46M | Sep 24, 2026 | Stock Option Exercise |
| Olivier Loeillot Officer, Director | Sep 21, 2026 | 5,426 | $976.68K | Sep 21, 2026 | Stock Option Exercise |
| Olivier Loeillot Officer, Director | Sep 4, 2026 | 3,035 | $503.51K | Sep 4, 2026 | Restricted Stock Vesting |
| Olivier Loeillot Officer, Director | Aug 20, 2026 | 5,426 | $976.68K | Aug 20, 2026 | Stock Option Exercise |
| Jason K. Garland Officer | Jul 16, 2026 | 530 | $79.50K | Jul 16, 2026 | Restricted Stock Vesting |
| Jason K. Garland Officer | Jun 25, 2026 | 733 | $106.29K | Jun 25, 2026 | Restricted Stock Vesting |
| Olivier Loeillot Officer, Director | Apr 21, 2026 | 3,832 | $536.48K | Apr 21, 2026 | Restricted Stock Vesting |
| Karen A. Dawes Director | Dec 17, 2025 | 275 | $44.28K | Dec 17, 2025 | Stock Option Exercise |
| Olivier Loeillot Officer, Director | Nov 25, 2025 | 7,041 | $1.20M | Nov 25, 2025 | Restricted Stock Vesting |
| James Bylund Officer | Nov 18, 2025 | 2,191 | $331.30K | Nov 18, 2025 | Restricted Stock Vesting |
| Anthony Hunt Director | Nov 13, 2025 | 20,000 | $3.09M | Nov 13, 2025 | Stock Option Exercise |
| Anthony Hunt Director | Nov 12, 2025 | 25,000 | $3.92M | Nov 12, 2025 | Option Granted - 03/01/2018 |
| Anthony Hunt Director | Sep 10, 2025 | 29,111 | $3.51M | Sep 10, 2025 | Restricted Stock Vesting |
Congress trades
7 trades in Repligen reported by 2 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Lisa McClain MI09 · spouse | Sold | Oct 31, 2025 | $1K–15K | Nov 21, 2025 |
| Lisa McClain MI09 · spouse | Bought | Oct 30, 2025 | $1K–15K | Nov 21, 2025 |
| Lisa McClain MI09 · spouse | Sold | Oct 30, 2025 | $1K–15K | Nov 21, 2025 |
| Lisa McClain MI09 · spouse | Bought | Jul 22, 2025 | $1K–15K | Aug 13, 2025 |
| Lisa McClain MI09 · spouse | Sold (part) | Jun 17, 2025 | $1K–15K | Aug 13, 2025 57 days late |
| Lisa McClain MI09 · spouse | Bought | Jun 11, 2025 | $1K–15K | Aug 13, 2025 63 days late |
| Jefferson Shreve IN06 | Sold | Apr 7, 2025 | $15K–50K | May 8, 2025 |
See a number that looks wrong?